BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) had its price objective reduced by equities research analysts at HC Wainwright from $7.00 to $5.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.
BTAI has been the subject of a number of other reports. Canaccord Genuity Group restated a “buy” rating and set a $7.00 price objective on shares of BioXcel Therapeutics in a report on Friday, August 30th. UBS Group cut their price objective on BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a report on Friday, August 9th.
Check Out Our Latest Research Report on BTAI
BioXcel Therapeutics Price Performance
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.55. The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same quarter in the previous year, the firm posted ($1.83) earnings per share. Equities research analysts anticipate that BioXcel Therapeutics will post -1.84 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of BioXcel Therapeutics in the second quarter worth about $39,000. Rosalind Advisors Inc. purchased a new position in BioXcel Therapeutics in the 2nd quarter worth approximately $51,000. XTX Topco Ltd grew its position in BioXcel Therapeutics by 49.0% in the second quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock valued at $60,000 after acquiring an additional 15,291 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of BioXcel Therapeutics during the fourth quarter valued at approximately $176,000. Finally, Vanguard Group Inc. lifted its position in shares of BioXcel Therapeutics by 0.9% during the first quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock worth $3,100,000 after purchasing an additional 9,912 shares in the last quarter. 30.68% of the stock is owned by hedge funds and other institutional investors.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Articles
- Five stocks we like better than BioXcel Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Buy P&G Now, Before It Sets A New All-Time High
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Dividends? Buy the Best Dividend Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.